Co-op CARs for targeting acute myeloid leukemia.
Cancer Cell
; 41(11): 1841-1843, 2023 11 13.
Article
de En
| MEDLINE
| ID: mdl-37832553
ABSTRACT
Chimeric antigen receptor (CAR) T cell therapies are limited by antigen escape and on-target/off-tumor toxicity. In addressing these challenges, Haubner et al. develop an "IF-BETTER" strategy. Their combinatorial chimeric co-stimulatory receptor with an attenuated CAR enhances acute myeloid leukemia (AML) killing while protecting healthy progenitors, highlighting the potential to leverage cooperative CAR designs.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Leucémie aigüe myéloïde
Limites:
Humans
Langue:
En
Journal:
Cancer Cell
Sujet du journal:
NEOPLASIAS
Année:
2023
Type de document:
Article